The Nasdaq Biotechnology index fell 23 percent in the first three months of 2016, its worst quarterly performance since 2002, and remains down one-third from its all-time high, reached last July. Andy Acker, a portfolio manager at Janus Capital Group who helps oversee $7 billion in healthcare assets, says the sell-off led to a steep discount to the sector's value, especially at a time of major innovation in developing treatments for cancer, heart disease and other illnesses that affect millions. Janus was the 10th-biggest investor in Medivation as of the end of the year, according to Thomson Reuters data, and Acker said multiple bidders could be interested in the company.
See the original post:
Biotech stock swoon sparks buyout interest: investor